Full Schedule

7:00 AM – 8:00 AM ADT

Coffee with Exhibitors

Location: Convention Hall

7:00 AM – 8:00 AM ADT

Poster Session A Set-Up

Location: Convention Hall

7:00 AM – 6:00 PM ADT

Lactation Room

Location: MR505

7:00 AM – 6:00 PM ADT

Registration

Location: Convention Hall Pre-Function

7:00 AM – 6:00 PM ADT

Speaker Ready Room

Location: MR102

8:00 AM – 8:15 AM ADT

Welcome to ICPE 2023

Location: Ballroom

Keynote Speaker: – Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada

Keynote Speaker: – Center for Pharmacoepidemiology and Treatment Science, Rutgers University

8:15 AM – 10:00 AM ADT

Town Hall: Global Regulatory Forum on Real-World Evidence; Sponsored by ISPE's RWE Collaborative SIG

Location: Ballroom

Moderator: – Rutgers, The State University of New Jersey

Keynote Speaker: – U.S. Food and Drug Administration

Keynote Speaker: – Health Canada

Panelist: – Oncology Center of Excellence, US Food and Drug Administration

Panelist: – Health Canada

Panelist: – Pharmaceuticals and Medical Devices Agency

Panelist: – Israel Ministry of Health

Panelist: – European Medicines Agency

Panelist: – Medicines and Healthcare products Regulatory Agency

8:00 AM – 6:00 PM ADT

Exhibits/Poster Session A

Location: Convention Hall

10:00 AM – 10:30 AM ADT

Break/Exhibits/Posters

Location: Convention Hall

10:30 AM – 12:00 PM ADT

Curriculum in Pharmacoepidemiology Training and Alignment with Updated Core Competencies: State of the Field and Educational Needs Assessment

Location: Argyle 1

Lead Speaker: – University of Florida

Speaker: – GW Pharmaceuticals, part of Jazz Pharmaceuticals

Speaker: – PEPI Consultancy Limited

Speaker: – Department of Pharmacy Practice and Science, University of Kentucky, Lexington, Kentucky, USA

Speaker: – University of Florida, Pharmaceutical Outcomes & Policy, Center for Drug Evaluation & Safety

Speaker: – European Medicines Agency

Speaker: – Discipline of Pharmacy, University of Technology Sydney, Sydney, NSW, Australia

Speaker: – U.S. Food and Drug Administration

Speaker: – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University

Speaker: – AbbVie

Speaker: – Optum Epidemiology

Speaker: – National Taiwan University

Speaker: – Pfizer, Inc.

Speaker: – UMKC

Speaker: – UNC Gillings School of Global Public Health

10:30 AM – 12:00 PM ADT

Data to Action: Leveraging Drug Utilization Research to Shift Clinical Practice and Health Policy

Location: Argyle 2

Lead Speaker: – University of Toronto

Speaker: – Syddansk Universitet

Speaker: – University of North Carolina at Chapel Hill

Speaker: – Registry of Senior Australians, South Australian Health and Medical Research Institute

10:30 AM – 12:00 PM ADT

Developing Code Lists for Pharmacoepidemiology: The How and Why?

Location: Argyle 3

Lead Speaker: – Genesis Research

Speaker: – Perelman School of Medicine at the University of Pennsylvania

Speaker: – BeiGene USA, Inc.

Speaker: – Odysseus Data Services Inc.

Speaker: – PPD, a part of Thermo Fisher Scientific

10:30 AM – 12:00 PM ADT

Privacy-Preserving Solutions for Real-World Data (RWD) Access and Collaboration: Challenges & Opportunities

Location: MR201

Lead Speaker: – Merck & Co. Inc.

Speaker: – Merck & Co., Inc., Rahway, NJ, United States

Speaker: – Aetion

Speaker: – Washington University School of Medicine

Speaker: – Replica Analytics

Speaker: – European Medicines Agency

Speaker: – Replica Analytics

10:30 AM – 12:00 PM ADT

Ready or Not, Here Come Estimands! The Emerging Attention to Causal Estimands in Real-World Evidence Studies

Location: MR202

Lead Speaker: – RTI Health Solutions

Speaker: – RTI Health Solutions

Speaker: – CAUSALab, Harvard T.H. Chan School of Public Health

Speaker: – European Medicines Agency

Speaker: – Rutgers University School of Public Health

Speaker: – US Food and Drug Administration

12:00 PM – 1:30 PM ADT

Committee Meetings

12:00 PM – 1:30 PM ADT

Exhibits/Posters

Location: Convention Hall

12:00 PM – 1:30 PM ADT

Lunch

Location: Ballroom

12:15 PM – 1:15 PM ADT

Spotlight Poster Session A

Location: Convention Hall

1:30 PM – 3:00 PM ADT

Applied Methods for Evaluating Effectiveness

Location: Argyle 1

Co-Moderator: – Pfizer

Co-Moderator: – UCL School of Pharmacy, University College London, London, United Kingdom

1:30 PM – 1:45 PM ADT

The Augmentation Therapy and Suicide Risk in Patients with Treatment-Resistant Depression Using Target Trial Emulation Framework

Location: Argyle 1

Presenting Author: – Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan

1:45 PM – 2:00 PM ADT

Long-term effects of intra-articular corticosteroid injections among knee osteoarthritis patients: an instrumental variable and propensity score analysis

Location: Argyle 1

Presenting Author: – University of Bristol

2:00 PM – 2:15 PM ADT

Combining randomized trials and observational studies data for comparison of treatment effects: an application to disease modifying therapies for multiple sclerosis

Location: Argyle 1

Presenting Author: – F. Hoffmann-La Roche Ltd

2:15 PM – 2:30 PM ADT

Comparative effectiveness of generic versus brand-name fluticasone-salmeterol dry powder inhalers to treat COPD

Location: Argyle 1

Presenting Author: – Brigham and Women's Hospital

2:30 PM – 2:45 PM ADT

Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction

Location: Argyle 1

Presenting Author: – Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ

2:45 PM – 3:00 PM ADT

Assessing comparability of osteoporosis treatment groups using real world healthcare data from the UK and Denmark: evaluating propensity score and negative control outcome methods to address confounding by indication

Location: Argyle 1

Presenting Author: – Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford

1:30 PM – 3:00 PM ADT

Due Before, During, and After Pregnancy

Location: Argyle 2

Co-Moderator: – Department of Epidemiology, Lazio Regional Health Service, Rome

Co-Moderator: – Bordeaux PharmacoEpi, INSERM CIC-P1401, Univ. Bordeaux, 33000 Bordeaux, France

1:30 PM – 1:45 PM ADT

Drug utilisation of valproate-containing medicinal products in women of childbearing potential in 5 European countries: a population-based network cohort study part of DARWIN EU®

Location: Argyle 2

Presenting Author: – Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford

1:45 PM – 2:00 PM ADT

Determinants of non-compliance with the pregnancy prevention program in women initiating oral isotretinoin therapy: a cohort study from the French nationwide claims database

Location: Argyle 2

Presenting Author: – Research on Healthcare Performance (RESHAPE), INSERM U1290, Université Claude Bernard Lyon 1, Lyon, France

2:00 PM – 2:15 PM ADT

Use of Oral Preventive and Emergency Hormonal Contraceptives: Recent Trends and Response to the U.S. Supreme Court's Dobbs Decision

Location: Argyle 2

Presenting Author: – University of Southern California

2:15 PM – 2:30 PM ADT

New Long-Acting Reversible Contraceptive Insertions More Than Doubled Among a Commercially Insured, U.S.-Based Outpatient Population from 2010 to 2020

Location: Argyle 2

Presenting Author: – UNC Gillings School of Global Public Health

2:30 PM – 2:45 PM ADT

Antithyroid Drug Use Before and During Pregnancy: Assessment of Switching Patterns and Changes Over Time

Location: Argyle 2

Presenting Author: – Leibniz Institute for Prevention Research and Epidemiology - BIPS

2:45 PM – 3:00 PM ADT

Lithium in Pregnancy: A Utilization Study in the Five Nordic Countries

Location: Argyle 2

Presenting Author: – Centre for Pharmacoepidemiology, Karolinska Institutet

1:30 PM – 3:00 PM ADT

Effectiveness of Anticoagulant Therapy

Location: Argyle 3

Co-Moderator: – Harvard Medical School

Co-Moderator: – Georgia State University

1:30 PM – 1:45 PM ADT

Comparative Effectiveness and Safety of Clopidogrel versus Aspirin in Patients With Acute Ischemic Stroke: A Nationwide Population-Based Study

Location: Argyle 3

Presenting Author: – School of Pharmacy, National Taiwan University, Taipei, Taiwan

1:45 PM – 2:00 PM ADT

Effectiveness and Safety of Apixaban, Rivaroxaban and Warfarin in Patients with Advanced Kidney Disease and Atrial Fibrillation: a Nationwide US Cohort Study

Location: Argyle 3

Presenting Author: – Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School

2:00 PM – 2:15 PM ADT

Emulating Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Venous Thromboembolism

Location: Argyle 3

Presenting Author: – School of Pharmacy, Sungkyunkwan University, South Korea

2:15 PM – 2:30 PM ADT

Framework for Assessing the Reproducibility of Observational Comparative Effectiveness Research: Direct Oral Anticoagulants and Ischemic or Hemorrhagic Events Case Study

Location: Argyle 3

Presenting Author: – Odysseus Data Services Inc.

2:30 PM – 2:45 PM ADT

The Comparative Effectiveness and Safety of Warfarin, Rivaroxaban, and Apixaban in Patients with Venous Thromboembolism: An Analysis of Three Real-World US Healthcare Databases

Location: Argyle 3

Presenting Author: – Harvard School of Public Health

2:45 PM – 3:00 PM ADT

Effectiveness and Safety of Reduced Dose Prasugrel versus Standard Dose Ticagrelor in East Asian Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Location: Argyle 3

Presenting Author: – School of Pharmacy, National Taiwan University, Taipei, Taiwan

1:30 PM – 3:00 PM ADT

Effectiveness of Antidiabetic Treatments

Location: MR109

Co-Moderator: – CERobs Consulting, LLC

Co-Moderator: – Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan

1:30 PM – 1:45 PM ADT

Heterogenous effects of sodium-glucose cotransporter-2 inhibitors on nephrolithiasis in older adults with type 2 diabetes

Location: MR109

Presenting Author: – Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy

1:45 PM – 2:00 PM ADT

Dipeptidyl Peptidase-4 Inhibitors and the Risk of Skin Cancer Among Patients with Type 2 Diabetes: Population-Based Cohort Study

Location: MR109

Presenting Author: – Harvard Medical School and Brigham and Women's Hospital

2:00 PM – 2:15 PM ADT

Healthcare utilization and cost associated with Empagliflozin in Older Adults with Type 2 Diabetes: Results from the EMPRISE study

Location: MR109

Presenting Author: – Division of Pharmacoepidemiology, Dept. of Medicine, Brigham & Women’s Hospital, Harvard Medical School

2:15 PM – 2:30 PM ADT

SGLT2 Inhibitors Associated with Decreased Risk of Nephrolithiasis Compared to GLP-1 Receptor Agonists: An Active Comparator, New User Cohort Study

Location: MR109

Presenting Author: – Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland

2:30 PM – 2:45 PM ADT

Sodium-Glucose Cotransporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists, and the Risk of Macrovascular, and Microvascular Complications Among Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

Location: MR109

Presenting Author: – School of Pharmacy, Sungkyunkwan University, Suwon, South Korea

2:45 PM – 3:00 PM ADT

Empagliflozin on the risk of retinopathy in patients with type 2 diabetes: Results from the EMPRISE study

Location: MR109

Presenting Author: – Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

1:30 PM – 3:00 PM ADT

Health Outcomes Research: What's in a Choice?

Location: MR201

Co-Moderator: – FDA/CDRH/ Office of Clinical Evidence and Analysis

Co-Moderator: – Research Triangle Institute

1:30 PM – 1:45 PM ADT

Association between angiotensin receptor blocker drug recalls and adverse clinical outcomes in patients with heart failure

Location: MR201

Presenting Author: – University of Pittsburgh

1:45 PM – 2:00 PM ADT

Regulatory and health technology assessment of cell and gene therapies in Europe: convergence or divergence?

Location: MR201

Presenting Author: – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University

2:00 PM – 2:15 PM ADT

Using a target trial framework to compare the effect of high/low opioid dosing strategies at post-surgical discharge on newly developed opioid use disorder

Location: MR201

Presenting Author: – Department of Pharmaceutical Care & Heath Systems, College of Pharmacy, University of Minnesota

2:15 PM – 2:30 PM ADT

Novel Uses of adaptive Designs to Guide provider Engagement in Electronic Health Records (NUDGE-EHR): a pragmatic adaptive database-randomized trial

Location: MR201

Presenting Author: – BWH Div of Pharmacoepidemiology and Pharmacoeconomics

2:30 PM – 2:45 PM ADT

Personalizing communication to improve medication adherence using reinforcement learning: a pragmatic randomized trial

Location: MR201

Presenting Author: – BWH Div of Pharmacoepidemiology and Pharmacoeconomics

2:45 PM – 3:00 PM ADT

Treatment Effectiveness of Oral Disease-Modifying Agent in Multiple Sclerosis Adjusting for Adherence Trajectories

Location: MR201

Presenting Author: – University of Houston, College of Pharmacy, Department of Pharmaceutical Health Outcomes and Policy

1:30 PM – 3:00 PM ADT

It Starts at The Very Beginning

Location: MR202

Co-Moderator: – University of Maryland School of Pharmacy, Baltimore, Maryland, USA

Co-Moderator: – Department of Pediatrics, Rutgers Robert Wood Johnson Medical School; Rutgers University, New Brunswick, NJ, USA

1:30 PM – 1:45 PM ADT

Health Canada advisory impact on the prevalence and trends of oral codeine use in the Pediatric Canadian population: A comparative study across provinces

Location: MR202

Presenting Author: – Research Centre - CHU Sainte-Justine

1:45 PM – 2:00 PM ADT

The use of ADHD medication and the risk of suicide attempt: A multinational population-based self-controlled case series study

Location: MR202

Presenting Author: – Groningen Research Institute of Pharmacy, Unit of PharmacoTherapy, ‐Epidemiology and ‐Economics, University of Groningen, Groningen, The Netherlands

2:00 PM – 2:15 PM ADT

Antidepressant Treatment Initiation Among Children with Long COVID

Location: MR202

Presenting Author: – University of Maryland School of Pharmacy, Baltimore, Maryland, USA

2:15 PM – 2:30 PM ADT

The Comparative Effectiveness and Safety of Amoxicillin Alone versus Amoxicillin/Clavulanate for the Outpatient Treatment of Acute Sinusitis in Children

Location: MR202

Presenting Author: – Brigham and Women's Hospital / Harvard Medical School

2:30 PM – 2:45 PM ADT

Early-life cancer risk among children conceived by assisted reproductive technology: A comparative nationwide cohort study from the French National Mother-Child Register "EPI-MERES"

Location: MR202

Presenting Author: – EPI-PHARE

2:45 PM – 3:00 PM ADT

Performance of different computable phenotypes for the identification of opioid-exposed infants in the electronic health record

Location: MR202

Presenting Author: – Department of Health Policy, VUMC

3:00 PM – 3:30 PM ADT

Break/Exhibits/Posters

Location: Convention Hall

3:30 PM – 5:00 PM ADT

Evaluating Challenges in Designing External Control Arm (ECA) Studies to Contextualize Effectiveness in Single-Arm Clinical Trials: A Case in Hematologic Malignancies

Location: Argyle 1

Lead Speaker: – Regeneron Pharmaceuticals

Speaker: – Regeneron Pharmaceuticals, Inc., Tarrytown, NY

Speaker: – Janssen Scientific Affairs, LLC

Speaker: – Eversana Life Science Services, LLC

Speaker: – National Taiwan University

Speaker: – Oncology Center of Excellence, US Food and Drug Administration

3:30 PM – 5:00 PM ADT

Integration of Systems Biology and Pharmacoepidemiology for Drug Repurposing Research: Lessons From the Drug Repurposing for Effective Alzheimer’s Medicines (DREAM) Study

Location: Argyle 2

Lead Speaker: – Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

Speaker: – Center for Pharmacoepidemiology and Treatment Science, Rutgers University

Speaker: – Johns Hopkins University School of Medicine

Speaker: – Clinical and Translational Neuroscience Section, National Institute on Aging, National Institutes of Health

3:30 PM – 5:00 PM ADT

Introducing CoLab: The Evolution of US-Canada International Collaboration on Drug Safety and Effectiveness

Location: Argyle 3

Lead Speaker: – Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School

Speaker: – Canadian Agency for Drugs and Technologies in Health

Speaker: – Health Canada

Speaker: – U.S. Food and Drug Administration

Speaker: – McGill University

3:30 PM – 5:00 PM ADT

Leveraging Real-World Insights to Inform Long-term Follow-up for Cell and Gene Therapies: Opportunities for Pharmacoepidemiologists

Location: MR201

Lead Speaker: – Novartis

Speaker: – Pfizer, Inc.

Speaker: – IQVIA

Speaker: – Dutch Medicines Evaluation Board

Speaker: – CSL Behring, King of Prussia, PA, USA

Speaker: – ARS Toscana, Florence, Italy

3:30 PM – 5:00 PM ADT

Sustainable Drug Use: Role of Pharmacoepidemiologists and Their Tools Addressing Environmental Impact of Drug Utilization

Location: MR202

Lead Speaker: – Uppsala university

Speaker: – Faculty or Medicine, University of Novi Sad

Speaker: – Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ

Speaker: – Uppsala University

5:15 PM – 6:45 PM ADT

Fear Not - Get The Shot

Location: Argyle 1

Co-Moderator: – PEPI Consultancy Limited

Co-Moderator: – IQVIA

5:15 PM – 5:30 PM ADT

Reporting Adverse Events Following Immunization in Ghana - Health Care Workers Experiences

Location: Argyle 1

Presenting Author: – Navrongo Health Research Centre

5:30 PM – 5:45 PM ADT

Concordance between analyses from the Moderna global safety database (GSD) and a US population-based study for COVID-19 vaccine, mRNA-1273

Location: Argyle 1

Presenting Author: – Moderna, Inc.

5:45 PM – 6:00 PM ADT

Active vaccine safety surveillance utilizing administrative data: evaluating the use of open + closed claims vs. closed claims alone

Location: Argyle 1

Presenting Author: – Aetion, Inc.

6:00 PM – 6:15 PM ADT

Myocarditis risk following immunization with Spikevax primary series and booster doses in a US administrative database

Location: Argyle 1

Presenting Author: – Moderna, Inc.

6:15 PM – 6:30 PM ADT

Evaluation of Potential Adverse Events Following COVID-19 mRNA Vaccination Among Adults Aged 65 Years and Older: A Self-Controlled Study in the U.S.

Location: Argyle 1

Presenting Author: – US Food and Drug Administration

6:30 PM – 6:45 PM ADT

Safety of concomitant administration of 23-valent polysaccharide pneumococcal vaccine and influenza vaccine among the elderly

Location: Argyle 1

Presenting Author: – Department of Health Convergence, College of Science and Industry Convergence, Ewha Womans University, Seoul, Republic of Korea

5:15 PM – 6:45 PM ADT

Finding Balance in The Rising Tides of Drug Safety in Older Adults: A Global Perspective

Location: Argyle 2

Co-Moderator: – Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill

Co-Moderator: – Dalhousie University

5:15 PM – 5:30 PM ADT

Use of cholinesterase inhibitors and non-steroidal anti-inflammatory drugs and the risk of peptic ulcers: a population-based self-controlled case series study

Location: Argyle 2

Presenting Author: – Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

5:30 PM – 5:45 PM ADT

Association of Anticholinergic Burden and Risk of Pneumonia in Aged People

Location: Argyle 2

Presenting Author: – School of Pharmacy and Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Taiwan

5:45 PM – 6:00 PM ADT

National Surveillance Using a Clinical Quality Indicator for Prolonged Antipsychotic Use Among Older Australians Living With Dementia Who Access Aged Care Services

Location: Argyle 2

Presenting Author: – UniSA Allied Health & Human Performance, University of South Australia

6:00 PM – 6:15 PM ADT

Effect of Non-benzodiazepine Hypnotics on Motor Vehicle Crashes among Older Adults: A Sequential Target Trial Emulation

Location: Argyle 2

Presenting Author: – Brown University School of Public Health

6:15 PM – 6:30 PM ADT

Association between antihypertensive medication initiation and risk of fractures among older adults in VA long-term care facilities

Location: Argyle 2

Presenting Author: – Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ

6:30 PM – 6:45 PM ADT

Cumulative sodium-glucose cotransporter 2 inhibitor exposure and incident dementia: a population-based cohort analysis

Location: Argyle 2

Presenting Author: – Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada

5:15 PM – 6:45 PM ADT

Lightning Session 1

Location: Argyle 3

Co-Moderator: – Radboud university medical center

Co-Moderator: – Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University

Co-Moderator: – OMNY Health

Co-Moderator: – London School of Hygiene & Tropical Medicine

5:15 PM – 5:20 PM ADT

Trends in Psychotropic Polypharmacy Among Medicaid-Enrolled Youths in One US State, 2015-2020

Location: Argyle 3

Presenting Author: – University of Maryland School of Pharmacy, Baltimore, Maryland, USA

5:20 PM – 5:25 PM ADT

Contribution of incident potentially inappropriate medications to polypharmacy-associated mortality in individuals 41-64 years of age

Location: Argyle 3

Presenting Author: – Veterans Aging Cohort Study Coordinating Center, VA Connecticut Healthcare System, West Haven, CT, 06516, USA

5:25 PM – 5:30 PM ADT

Ten-year trajectories of multimorbidity and impact on polypharmacy in older people

Location: Argyle 3

Presenting Author: – Laval University

5:30 PM – 5:35 PM ADT

Depressive Symptoms and Polypharmacy Among Adults: A Population-Based Analysis Using National Health and Nutrition Examination Survey (NHANES) Data

Location: Argyle 3

Presenting Author: – UNC Chapel Hill Gillings School of Global Public Health

5:45 PM – 5:50 PM ADT

Characterizing Medication Use Patterns Among Pregnant and non-Pregnant Patients with COVID-19 in the Sentinel System

Location: Argyle 3

Presenting Author: – Harvard Pilgrim HealthCare & Harvard Medical School

5:50 PM – 5:55 PM ADT

Disorders of glycemic control in child following exposure to antibiotics: a nationwide cohort study

Location: Argyle 3

Presenting Author: – School of Pharmacy, Sungkyunkwan University

5:55 PM – 6:00 PM ADT

Differences in Urinary Tract Infection Incidence During Pregnancy by Racial and Ethnic Group in an Integrated Health System in the US, 2010-2022

Location: Argyle 3

Presenting Author: – Kaiser Permanente Washington Health Research Institute

6:00 PM – 6:05 PM ADT

Prescription Medication Use During Pregnancy in the United States from 2011 to 2019

Location: Argyle 3

Presenting Author: – Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States

6:15 PM – 6:20 PM ADT

Urinary Escherichia coli antimicrobial-resistance trends and antibiotic use in Australian Residential Aged Care from 2016 – 2018: an ecological study

Location: Argyle 3

Presenting Author: – University of Technology Sydney

6:20 PM – 6:25 PM ADT

Trends and inequalities in statin use for the primary and secondary prevention of cardiovascular disease

Location: Argyle 3

Presenting Author: – London School of Hygiene and Tropical Medicine

6:25 PM – 6:30 PM ADT

Increase in Mental Health Conditions and Psychotropic Prescribing in Teenage Girls During the COVID-19 Pandemic in the US

Location: Argyle 3

Presenting Author: – Brigham and Women's Hospital/Harvard Medical School

6:30 PM – 6:35 PM ADT

Non-antibiotic prescription drug use among Danish children and adolescents 2005-2021

Location: Argyle 3

Presenting Author: – Clinical Pharmacology, Pharmacy and Environmental Medicine, Dept. of Puiblic Health, University of Southern Denmark

5:15 PM – 6:45 PM ADT

Vaccine Potpourri

Location: MR109

Co-Moderator: – University of Pennsylvania School of Medicine

Co-Moderator: – Infectious Disease Epidemiology, Moderna Therapeutics Inc.

5:15 PM – 5:30 PM ADT

The Contribution of Immunization Information System Data to Claims-Based Capture of Vaccines Used to Prevent Mpox and Implications for Claims-Based Mpox Surveillance

Location: MR109

Presenting Author: – Optum Epidemiology

5:30 PM – 5:45 PM ADT

High-Dose Influenza Vaccine Receipt: Geographic Variation in Racial Health Disparities

Location: MR109

Presenting Author: – Brown University School of Public Health

5:45 PM – 6:00 PM ADT

Effectiveness of Recombinant Zoster Vaccine Against Herpes Zoster in a Real-World Setting. The Vaccine Safety Datalink

Location: MR109

Presenting Author: – Kaiser Permanente Northern California, Vaccine Study Center

6:00 PM – 6:15 PM ADT

Comparing Vaccination Timeliness among U.S. Children in the 2019 and 2021 National Immunization Survey-Child

Location: MR109

Presenting Author: – University of Montana Center for Population Health Research

6:15 PM – 6:30 PM ADT

Statins may modulate the effectiveness of the flu vaccine according to the type of respiratory outcome: Results from the Statin Treatment OPtions during vaccination against inFLUenza (STOPFlu) study

Location: MR109

Presenting Author: – University of Exeter

6:30 PM – 6:45 PM ADT

Assessment of Neurological and Immunological Adverse Events Following Childhood Pneumococcal Vaccination: a Population-Based Self-Controlled Risk Interval Analysis

Location: MR109

Presenting Author: – School of Pharmacy, Sungkyunkwan University, South Korea

5:15 PM – 6:45 PM ADT

Mixing Up The Methods in Drug Utilization Research

Location: MR201

Co-Moderator: – Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, ETH Zurich, Zurich, Switzerland

Co-Moderator: – School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan

5:15 PM – 5:30 PM ADT

Location: MR201

Presenting Author: – University of Oxford

5:30 PM – 5:45 PM ADT

Using Day-Level Registry Data to Assess Heterogeneous and Time-Varying Medication Exposure Patterns in Patients Receiving Long-Term Outpatient Antibiotic Therapy, 2015-2022

Location: MR201

Presenting Author: – University of North Carolina at Chapel Hill

5:45 PM – 6:00 PM ADT

Projected Impact of Weight-Loss Medication Use on Racial-Ethnic Disparities in Adolescent Obesity

Location: MR201

Presenting Author: – University of Pittsburgh School of Medicine

6:00 PM – 6:15 PM ADT

Approaches to the Description of Patterns of Care after Colitis Diagnosis in Melanoma Patients Treated with Immune Checkpoint Inhibitors (ICIs)

Location: MR201

Presenting Author: – Bristol Myers Squibb

6:15 PM – 6:30 PM ADT

Characteristics of US Middle-Aged Adults with Polypharmacy: An Unsupervised Machine Learning Approach

Location: MR201

Presenting Author: – Panalgo

6:30 PM – 6:45 PM ADT

Assessing the performance of group-based trajectory modelling method to discover patterns of medication adherence

Location: MR201

Presenting Author: – Cytel

5:15 PM – 6:45 PM ADT

COVID Consequences

Location: MR202

Co-Moderator: – Harvard TH Chan School of Public Health

Co-Moderator: – Drug Safety Research Unit

5:15 PM – 5:30 PM ADT

Association between COVID-19 vaccination and healthcare contacts for menstrual disturbance and pre- and post-menopausal bleeding – a nationwide cohort study of 3 million Swedish women

Location: MR202

Presenting Author: – School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

5:30 PM – 5:45 PM ADT

Stroke, Myocardial Infarction, and Pulmonary Embolism after COVID-19 mRNA bivalent booster in People Aged 50 Years or Older

Location: MR202

Presenting Author: – EPI-PHARE (ANSM/CNAM)

5:45 PM – 6:00 PM ADT

Myocarditis associated with SARS-CoV-2 vaccines by dose and brand in three European countries using large electronic health care data sources: a self-controlled risk interval study  in the COVID-19 vaccine monitor study

Location: MR202

Presenting Author: – Department of Biostatistics and Research support, Julius Center for Health sciences and Primary care, University Medical Center Utrecht, the Netherlands

6:00 PM – 6:15 PM ADT

Cerebral Venous Sinus Thrombosis Without Thrombocytopenia After ChAdOx1 nCoV-19 Vaccination

Location: MR202

Presenting Author: – Seoul National University Hospital

6:15 PM – 6:30 PM ADT

Effect of COVID-19 vaccination on thromboembolic and cardiovascular complications following SARS-CoV-2 infection

Location: MR202

Presenting Author: – IDIAP Jordi Gol

6:30 PM – 6:45 PM ADT

Risk of Guillain-Barré syndrome following COVID-19 vaccines: a nationwide self-controlled case series study

Location: MR202

Presenting Author: – EPI-PHARE

7:00 PM – 8:00 PM ADT

SIG Meetings

8:00 PM – 10:00 PM ADT

PDS Editorial Board

Location: MR605

8:30 PM – 11:00 PM ADT

Students/Early Career Professionals Meet & Greet

Location: The Roxbury Urban Dive Bar